SRTS

AI Memo

Sensus Healthcare

As of 2026-09-25/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Proposed hospital-based reimbursement increase • 2026-12-24

Base target: $3 / p=60% prob

Biggest risk

Q2 revenue fell sharply despite reported pipeline improvement. Financing-dependent recognition and uncertain conversion could leave results volatile; the proposed reimbursement increase might not be finalized. [#SEC-8K-2026-08-13]

Invalidation

Break below $2 or thesis failure.

What would change my mind?

Recognition of the eight delayed units, stronger CPT-related conversion and a favorable final reimbursement decision could improve revenue visibility. These outcomes remain to be demonstrated. [#SEC-8K-2026-08-13]

Research note

Recommendation

—

Confidence

medium

As of

2026-09-25

Base target

p=60%

Bull target

p=20%

Bear target

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q3 recognition of eight previously sold units
Convert CPT-related interest into sustained sales
Recognition of the eight delayed units, stronger CPT-related conversion and a favorable final reimbursement decision could improve revenue visibility.

BearKey bullets

Q2 revenue was $2.3 million, down $5.0 million year over year; a stronger reported pipeline has not yet produced sustained growth.
[#SEC-8K-2026-08-13]
Small market capitalization and low coverage increase valuation and liquidity uncertainty.

WatchKey bullets

Proposed hospital-based reimbursement increase

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $3 (p=60%)

Target spread vs base: +32% / -48%

Scenario probabilities

Bull Target: $4 (p=20%)Base Target: $3 (p=60%)Bear Target: $2 (p=20%)

Commentary

Company-reported pipeline and reimbursement developments are encouraging, but the Q2 revenue decline tempers the tone. The packet does not verify the post-release share-price reaction, analyst revisions or current social coverage; zero values in the sentiment fields denote unavailable data, not neutral observations. Director open-market purchases in August are disclosed but do not establish operating improvement. [#SEC-FORM4-2026-08-25] [#SEC-FORM4-2026-08-31]

As of 2026-09-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q3 recognition of eight previously sold units
Convert CPT-related interest into sustained sales

Scenarios

Bull Target (Scenario probability)

$4 / p=20% prob

Base Target (Scenario probability)

$3 / p=60% prob

Bear Target (Scenario probability)

$2 / p=20% prob

Analysis 2026-09-25 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.10

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-24
Proposed hospital-based reimbursement increase
The company reported that CMS proposed a 26% increase in the hospital-based SRT delivery code. Finalization could improve provider economics, but the proposal is not an enacted reimbursement change. [#SEC-8K-2026-08-13]
Prob 45.00% • Move 15.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Q3 recognition of eight previously sold units
2026-12-24
Sensus reported Q2 revenue of $2.3 million, down $5.0 million year over year. Financing-approval timing prevented recognition of eight units in Q2; the company said the approvals were subsequently completed and the revenue would be recognized in Q3. This would recover timing-related revenue, not establish incremental demand. [#8-K-2026-08-13] [#SEC-8K-2026-08-13]
Prob 75% • Move 8% • Priced-in 50%

Long-term Catalysts

Months to a year

Convert CPT-related interest into sustained sales
2027-09-25
Management reported stronger customer engagement and a sales pipeline following CPT-code implementation, including interest from physician groups and health systems. Sustained unit sales and revenue growth remain unproven after the Q2 decline. [#SEC-8K-2026-08-13]
Prob 50% • Move 22% • Priced-in 30%

Risks

Q2 revenue was $2.3 million, down $5.0 million year over year; a stronger reported pipeline has not yet produced sustained growth. [#SEC-8K-2026-08-13]
Small market capitalization and low coverage increase valuation and liquidity uncertainty.
The proposed 26% hospital-based code increase remains subject to a final CMS decision. [#SEC-8K-2026-08-13]
Third-party financing timing delayed recognition of eight units, illustrating quarterly revenue volatility. [#SEC-8K-2026-08-13]

Peers

Symbol	Summary
BSX	Broad medical-device reference; its much larger scale makes direct valuation comparison weak.
NNOX	Small-cap medical-imaging reference, but not a verified direct competitor in superficial radiotherapy.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-25